Valeant’s Improved Allergan Offer Won’t Be An All Cash Deal – ValueWalk Premium
valeant pharmaceuticals

Valeant’s Improved Allergan Offer Won’t Be An All Cash Deal

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) has announced it will not make an all-cash bid for drug maker Allergan, Inc. (NYSE:AGN), contrary to the expectations of many people.

Earlier Allergan rejected Valeant’s offer citing the high stock component and steep cost cutting proposals.
Allergan's rejection of Valeant offer

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
0